Novo Nordisk’s Alhemo® Recommended for European Approval as First Once-Daily Subcutaneous Treatment for Haemophilia A and B with Inhibitors

(IN BRIEF) Novo Nordisk’s Alhemo® (concizumab) has been recommended for approval by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP). If approved, Alhemo® will become the first once-daily subcutaneous prophylactic treatment for people aged 12 … Read the full press release →